Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

FLECTOR Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Flector, and when can generic versions of Flector launch?

Flector is a drug marketed by Inst Biochem and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has ten patent family members in nine countries.

The generic ingredient in FLECTOR is diclofenac epolamine. There are forty-seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the diclofenac epolamine profile page.

US ANDA Litigation and Generic Entry Outlook for Flector

Flector was eligible for patent challenges on December 31, 1968.

Annual sales in 2017 were $39mm indicating the motivation for generic entry (peak sales were $278mm in 2012).

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Drug patent expirations by year for FLECTOR
Drug Prices for FLECTOR

See drug prices for FLECTOR

Drug Sales Revenue Trends for FLECTOR

See drug sales revenues for FLECTOR

Recent Clinical Trials for FLECTOR

Identify potential brand extensions & 505(b)(2) entrants

IBSA Institut Biochimique SAPhase 4
Actavis Inc.Phase 3
PfizerPhase 4

See all FLECTOR clinical trials

Recent Litigation for FLECTOR

Identify potential future generic entrants

District Court Litigation
Case NameDate
Altergon SA v. Actavis Laboratories UT, Inc.2015-10-01

See all FLECTOR litigation

Pharmacology for FLECTOR
Synonyms for FLECTOR
2-((2,6-Dichlorophenyl)amino)benzeneacetic acid, compd. with 1-pyrrolidineethanol (1:1)
2-(pyrrolidin-1-yl)ethan-1-ol 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate
2-[2-(2,6-dichloroanilino)phenyl]acetic acid; 2-pyrrolidin-1-ylethanol
2-[2-(2,6-dichloroanilino)phenyl]acetic acid;2-pyrrolidin-1-ylethanol
Aclonac, Cataflam, Voltaren
Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-, compd. with 1-pyrrolidineethanol (1:1)
DHEP plaster
Diclofenac acid N-(2-hydroxyetheyl) pyrrolidine salt
Diclofenac-N-(2-hydroxyethyl) pyrrolidine
Flector (TN)
N-(2-Hydroxyethyl)pyrrolidinium (2-((2,6-dichlorophenyl)amino)phenyl)acetate
Paragraph IV (Patent) Challenges for FLECTOR
Tradename Dosage Ingredient NDA Submissiondate
FLECTOR PATCH;TOPICAL diclofenac epolamine 021234 2015-06-26

US Patents and Regulatory Information for FLECTOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Inst Biochem FLECTOR diclofenac epolamine PATCH;TOPICAL 021234-001 Jan 31, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.